Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03845712 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
A Phase 2 study of Thymidine Kinase 2 Deficiency, sponsored by UCB Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 8
- Study locations
NCT03845712 is a Phase 2 study of Thymidine Kinase 2 Deficiency that is active but no longer recruiting, run by UCB Biosciences. The registered enrollment target is 47 participants. The trial reports 8 study locations across 2 states.
The verdict
NCT03845712, a Phase 2 study of Thymidine Kinase 2 Deficiency, is active but no longer recruiting, sponsored by UCB Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.
Conditions Studied
Interventions
- DRUG doxecitine and doxribtimine
Study Locations (8)
Other
- Tk0102 4038 - Haifa
- Tk0102 4039 - Holon
- Tk0102 4037 - Nehariya
- Tk0102 3102 - Barcelona
- Tk0102 3121 - Esplugues de Llobregat
- Tk0102 3031 - Madrid
- Tk0102 3101 - Seville
New York
- Tk0102 1005 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-07-05 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03845712
The ClinicalTrials.gov registry entry for NCT03845712 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thymidine Kinase 2 Deficiency appearing as the primary indexed condition, and to 1 intervention - of which doxecitine and doxribtimine is the first listed.
NCT03845712 reports 8 study locations spanning 2 distinct geographic areas - top geographies include Other, New York.
Frequently Asked Questions
What is clinical trial NCT03845712 about?
NCT03845712 is a clinical study titled "An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency". This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and ...
What is the current status of trial NCT03845712?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2019-07-05. Estimated completion is 2026-06-30.
What conditions does trial NCT03845712 study?
This clinical trial studies the following conditions: Thymidine Kinase 2 Deficiency.
What interventions are being tested in trial NCT03845712?
The interventions under investigation include: doxecitine and doxribtimine (DRUG).
Who is sponsoring clinical trial NCT03845712?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03845712 being conducted?
This trial has 8 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thymidine Kinase 2 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.